Changshan Song
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Changshan Song has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
Shunfu Deng
Foshan Fosun Chancheng Hospital
6 shared publicationsHui Hu
Foshan Fosun Chancheng Hospital
5 shared publicationsMinqian Huang
Foshan Fosun Chancheng Hospital
4 shared publications- Bairu Shen
Thoracic Surgery, Foshan Clinical Medical School of Guangzhou University of Chinese Medicine, Guangdong Province, China
3 shared publications Jiaqing Wang
Foshan Fosun Chancheng Hospital
3 shared publicationsKaixi Liu
Foshan Fosun Chancheng Hospital
3 shared publications
Latest Publications
- 16 June 2026
- Published by SAGE Publications in Acupuncture & Electro-Therapeutics Research: International Journal of Integrated Medicine
Bibliometric Analysis and Knowledge Mapping of Acupuncture in Adjuvant Treatment of Lung Cancer
Objective: This bibliometric analysis aimed to comprehensively investigate the research landscape and developmental trends of publications on acupuncture as an adjunctive treatment for lung cancer from 2006 to 2026. Methods: Publications related to acupuncture and lung cancer were retrieved from the PubMed database, spanning the period from 2006 to 2026. Bibliometric mapping was constructed using the bibliometrix package in R. Through co-occurrence analysis, clustering algorithms, network analysis, and time series analysis, this study identified high-frequency keywords, research themes, collaboration patterns, and the evolution of research hotspots. Results: A significant increase in publication volume was observed, with the annual output peaking in 2025, representing a more than fivefold increase compared with 2006. Original research articles account for 73.7% of the total publications, indicating that the empirical foundation is increasingly strengthened. China takes a leading position in terms of the number of publications and international cooperation networks and is a central hub for global academic cooperation. Research mainly focuses on five fields such as basic experiments, clinical efficacy evaluation, and comprehensive treatment strategies. Research hotspots are shifting from being technology-centered to precise staging and multimode integration. Conclusion: The field of acupuncture in the treatment of lung cancer is developing steadily. In the future, more attention should be paid to the integration of basic research and clinical translation. It is recommended to strengthen international multicenter clinical trials and mechanism research to promote the standardized application of acupuncture in the comprehensive treatment of lung cancer.
- 16 June 2026
- Published by SAGE Publications in Acupuncture & Electro-Therapeutics Research: International Journal of Integrated Medicine
Bibliometric Analysis and Knowledge Mapping of Acupuncture in Adjuvant Treatment of Lung Cancer
Objective: This bibliometric analysis aimed to comprehensively investigate the research landscape and developmental trends of publications on acupuncture as an adjunctive treatment for lung cancer from 2006 to 2026. Methods: Publications related to acupuncture and lung cancer were retrieved from the PubMed database, spanning the period from 2006 to 2026. Bibliometric mapping was constructed using the bibliometrix package in R. Through co-occurrence analysis, clustering algorithms, network analysis, and time series analysis, this study identified high-frequency keywords, research themes, collaboration patterns, and the evolution of research hotspots. Results: A significant increase in publication volume was observed, with the annual output peaking in 2025, representing a more than fivefold increase compared with 2006. Original research articles account for 73.7% of the total publications, indicating that the empirical foundation is increasingly strengthened. China takes a leading position in terms of the number of publications and international cooperation networks and is a central hub for global academic cooperation. Research mainly focuses on five fields such as basic experiments, clinical efficacy evaluation, and comprehensive treatment strategies. Research hotspots are shifting from being technology-centered to precise staging and multimode integration. Conclusion: The field of acupuncture in the treatment of lung cancer is developing steadily. In the future, more attention should be paid to the integration of basic research and clinical translation. It is recommended to strengthen international multicenter clinical trials and mechanism research to promote the standardized application of acupuncture in the comprehensive treatment of lung cancer.
- Open Access
- 14 February 2026
- Published by Springer Nature in Discover Oncology
- Vol. 17  (1)
Factors predicting spread through air spaces (STAS) preoperative for T1a–b non-small cell lung cancer
Background Spread through air spaces (STAS) is a critical factor affecting the prognosis of lung cancer patients and has potential to guide surgical decision-making. Clinical trials have shown that lobectomy reduces recurrence risk more effectively than sub lobectomy in STAS-positive patients. However, STAS diagnosis currently relies on postoperative pathology, and there is a lack of accurate preoperative diagnostic methods. Preoperative prediction of STAS status remains an unmet need. Methods We systematically searched 8 databases (Chinese: CBM, CNKI, WanFang Data, VIP; English: PubMed, Cochrane Library, Web of Science, Embase) from January 2015 to December 2023 using both Chinese and English search terms. Chinese terms included “airspace dissemination”, “lung cancer”, “prediction”; English terms included “spread through air spaces”, “STAS”, “prediction”, “Stage IA Lung cancer”, “Lung Neoplasms [Mesh]”. Retrospective comparative studies analyzing preoperative indicators and postoperative STAS pathological results were included. Literature quality was assessed using the Newcastle-Ottawa Scale (NOS), and data were extracted with RevMan 5.4. Meta-analysis was performed using Stata-64 software. Results A total of 17 studies involving 5053 patients were included, with 1942 STAS-positive (STAS+) and 3111 STAS-negative (STAS-) patients. Quantitative analysis showed that STAS was significantly associated with preoperative spiculation (OR 3.73, 95%CI 2.24–6.21, p < 0.01), lobulation (OR 3.20, 95%CI 2.47–4.15, p < 0.01), pleural indentation (OR 2.14, 95%CI 1.71–2.68, p < 0.01), cavitation (OR 2.06, 95%CI 1.51–2.83, p < 0.01), and consolidation tumor ratio (CTR) (OR 4.87, 95%CI 3.29–7.22, p < 0.01). Conclusions Preoperative imaging characteristics including spiculation, lobulation, pleural indentation, cavitation, and CTR can effectively predict STAS status in early-stage lung cancer. These indicators provide valuable references for surgeons in selecting appropriate surgical methods for early non-small cell lung cancer patients.
- 14 February 2026
- Published by Springer Nature in Discover Oncology
- Vol. 17  (1)
Open AccessFactors predicting spread through air spaces (STAS) preoperative for T1a–b non-small cell lung cancer
Background Spread through air spaces (STAS) is a critical factor affecting the prognosis of lung cancer patients and has potential to guide surgical decision-making. Clinical trials have shown that lobectomy reduces recurrence risk more effectively than sub lobectomy in STAS-positive patients. However, STAS diagnosis currently relies on postoperative pathology, and there is a lack of accurate preoperative diagnostic methods. Preoperative prediction of STAS status remains an unmet need. Methods We systematically searched 8 databases (Chinese: CBM, CNKI, WanFang Data, VIP; English: PubMed, Cochrane Library, Web of Science, Embase) from January 2015 to December 2023 using both Chinese and English search terms. Chinese terms included “airspace dissemination”, “lung cancer”, “prediction”; English terms included “spread through air spaces”, “STAS”, “prediction”, “Stage IA Lung cancer”, “Lung Neoplasms [Mesh]”. Retrospective comparative studies analyzing preoperative indicators and postoperative STAS pathological results were included. Literature quality was assessed using the Newcastle-Ottawa Scale (NOS), and data were extracted with RevMan 5.4. Meta-analysis was performed using Stata-64 software. Results A total of 17 studies involving 5053 patients were included, with 1942 STAS-positive (STAS+) and 3111 STAS-negative (STAS-) patients. Quantitative analysis showed that STAS was significantly associated with preoperative spiculation (OR 3.73, 95%CI 2.24–6.21, p < 0.01), lobulation (OR 3.20, 95%CI 2.47–4.15, p < 0.01), pleural indentation (OR 2.14, 95%CI 1.71–2.68, p < 0.01), cavitation (OR 2.06, 95%CI 1.51–2.83, p < 0.01), and consolidation tumor ratio (CTR) (OR 4.87, 95%CI 3.29–7.22, p < 0.01). Conclusions Preoperative imaging characteristics including spiculation, lobulation, pleural indentation, cavitation, and CTR can effectively predict STAS status in early-stage lung cancer. These indicators provide valuable references for surgeons in selecting appropriate surgical methods for early non-small cell lung cancer patients.
- 15 July 2025
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 297, 117966
Rational design of NAMPT-based dual inhibitors with improved drug-like and pharmacokinetic properties for cancer treatment
- 15 July 2025
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 297, 117966
Rational design of NAMPT-based dual inhibitors with improved drug-like and pharmacokinetic properties for cancer treatment
- Open Access
- 1 January 2025
- Published by Francis Academic Press Ltd. in Academic Journal of Medicine & Health Sciences
- Vol. 6  (1)
The value of AREG and MSLN levels in the adjuvant diagnosis of breast cancer
To explore the application value of the levels of amphotericin (AREG) and mesothelin (MSLN) in the auxiliary diagnosis of breast cancer. Serum samples were collected from 46 patients with pathological diagnosis of suspected breast cancer and 46 healthy controls, and the levels of AREG and MSLN were measured by enzyme-linked immunosorbent assay (ELISA) and other methods to analyse their relationship with clinicopathological features of breast cancer, and the diagnostic efficacy of the two individually and in combination was evaluated by statistical methods. Serum AREG and MSLN levels were significantly higher in breast cancer patients than in healthy controls, and they were correlated with clinicopathological features such as pathological type, lymph node metastasis and pathological stage. The diagnostic accuracy of the combined test was higher than that of the individual test. AREG and MSLN levels are valuable in the adjuvant diagnosis of breast cancer, and the combination of these two tests is expected to improve the early diagnosis of breast cancer and provide a more reliable basis for clinical treatment decisions.
- 1 January 2025
- Published by Francis Academic Press Ltd. in Academic Journal of Medicine & Health Sciences
- Vol. 6  (1)
Open AccessThe value of AREG and MSLN levels in the adjuvant diagnosis of breast cancer
To explore the application value of the levels of amphotericin (AREG) and mesothelin (MSLN) in the auxiliary diagnosis of breast cancer. Serum samples were collected from 46 patients with pathological diagnosis of suspected breast cancer and 46 healthy controls, and the levels of AREG and MSLN were measured by enzyme-linked immunosorbent assay (ELISA) and other methods to analyse their relationship with clinicopathological features of breast cancer, and the diagnostic efficacy of the two individually and in combination was evaluated by statistical methods. Serum AREG and MSLN levels were significantly higher in breast cancer patients than in healthy controls, and they were correlated with clinicopathological features such as pathological type, lymph node metastasis and pathological stage. The diagnostic accuracy of the combined test was higher than that of the individual test. AREG and MSLN levels are valuable in the adjuvant diagnosis of breast cancer, and the combination of these two tests is expected to improve the early diagnosis of breast cancer and provide a more reliable basis for clinical treatment decisions.
- 5 December 2024
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 283, 117141
Small molecule inhibitors targeting PD-L1, CTLA4, VISTA, TIM-3, and LAG3 for cancer immunotherapy (2020–2024)
- 5 December 2024
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 283, 117141
Small molecule inhibitors targeting PD-L1, CTLA4, VISTA, TIM-3, and LAG3 for cancer immunotherapy (2020–2024)
- 1 April 2024
- Published by China Scientific Research Publishing Pte. Ltd. in JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS
- Vol. 38  (4) , 3135-3146
Exosomal miR-522-3p Transferred from Cancer-associated Fibroblasts Promotes Lung Cancer Cell Progression via Regulating ZRANB2 Expression
Objective: This study aimed to investigate the molecular insights by which microRNA (miR-522-3p) in cancer-associated fibroblast (CAF) derived exosomes regulate lung cancer cell growth, proliferation, and invasive capabilities. Method: CAFs and normal fibroblasts (NFs) were isolated from lung cancer and adjacent non-cancerous/normal tissues and identified. Exosomes secreted from CAFs and NFs were isolated to analyze their effects on lung cancer cell proliferation, migration, and invasion by Cell Counting Kit-8 (CCK-8), colony formation, and Transwell assays. Next-generation sequencing (NGS) technology was applied to analyze microRNAs (miRNA) expression within the exosomes, specificaly measuring miR-522-3p. Additionally, a dual-luciferase reporter gene assay was utilized to validate the binding of zinc-finger RAN-binding domain-containing protein 2 (ZRANB2) to miR-522-3p. Results: The proliferation ability of cells in the CAF-exosomes (exo) groups significantly increased compared to NF-exo group (p < 0.05). Up-regulated miR-522-3p expression level was found in CAFs-exo (p < 0.001). Functional experiments demonstrated that miR-522-3p inhibitor can suppress lung cancer cell proliferation, migration, and invasion compared to the control inhibitor-exo groups (p < 0.05). ZRANB2 was a target gene of miR-522-3p. Conclusions: The present study highlights the role of CAFs in promoting lung cancer progression and metastasis via exosomal miR-522-3p, suggesting that the inhibition of CAF-derived miR-522-3p is an alternative modality for lung cancer treatment. These outcomes also provide a new perspective for further research on the lung cancer microenvironment and the development of treatment strategies.
- 1 April 2024
- Published by China Scientific Research Publishing Pte. Ltd. in JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS
- Vol. 38  (4) , 3135-3146
Exosomal miR-522-3p Transferred from Cancer-associated Fibroblasts Promotes Lung Cancer Cell Progression via Regulating ZRANB2 Expression
Objective: This study aimed to investigate the molecular insights by which microRNA (miR-522-3p) in cancer-associated fibroblast (CAF) derived exosomes regulate lung cancer cell growth, proliferation, and invasive capabilities. Method: CAFs and normal fibroblasts (NFs) were isolated from lung cancer and adjacent non-cancerous/normal tissues and identified. Exosomes secreted from CAFs and NFs were isolated to analyze their effects on lung cancer cell proliferation, migration, and invasion by Cell Counting Kit-8 (CCK-8), colony formation, and Transwell assays. Next-generation sequencing (NGS) technology was applied to analyze microRNAs (miRNA) expression within the exosomes, specificaly measuring miR-522-3p. Additionally, a dual-luciferase reporter gene assay was utilized to validate the binding of zinc-finger RAN-binding domain-containing protein 2 (ZRANB2) to miR-522-3p. Results: The proliferation ability of cells in the CAF-exosomes (exo) groups significantly increased compared to NF-exo group (p < 0.05). Up-regulated miR-522-3p expression level was found in CAFs-exo (p < 0.001). Functional experiments demonstrated that miR-522-3p inhibitor can suppress lung cancer cell proliferation, migration, and invasion compared to the control inhibitor-exo groups (p < 0.05). ZRANB2 was a target gene of miR-522-3p. Conclusions: The present study highlights the role of CAFs in promoting lung cancer progression and metastasis via exosomal miR-522-3p, suggesting that the inhibition of CAF-derived miR-522-3p is an alternative modality for lung cancer treatment. These outcomes also provide a new perspective for further research on the lung cancer microenvironment and the development of treatment strategies.
- Open Access
- 2 June 2022
- Published by Hindawi Limited in Journal of Immunology Research
- Vol. 2022, 1-13
Immunotherapy and Antivascular Targeted Therapy in Patients’ Treatment with Concurrent Malignant Tumors after Organ Transplantation: Opportunity or Challenge
Objective. To analyze the therapeutic effects and organ rejection of anti-PD-1 immunotherapy or antivascular targeting therapy on patients with combined malignancies after organ transplantation. Methods. We collected retrospective studies on “post-transplantation, cancer, immunotherapy, and vascular targeting therapy” in Embase, Wanfang database, Cochrane Library, VIP databases, CNKI, and PubMed, and the case data were organized and analyzed. Results. Data from only 40 papers met our requirements, which included 2 literature reviews, 4 original researches, and 34 case reports from 2016 to 2020. A total of 40 studies involving 66 patients were included, who were divided into 3 groups (patients using CTLA-4 inhibitors, group 1; patients who received sequential or concurrent anti-PD-1 and anti-CTLA-4 therapy, group 2; and patients using PD-1/PD-L1 inhibitors, group 3). There was no statistical difference in patients’ DCR between the three groups ( ). Also, compared with group 2, there was no statistically significant difference in recipient organ rejection in group 1 and group 3 ( ). The DCR rate for antivascular targeted therapy is approximately 60%. Conclusions. Immunotherapy should be carefully selected for patients with combined malignancies after organ transplantation. Antivascular targeted therapy is one of the options worth considering; the risk of side effects of drug therapy is something that needs to be closely monitored when combined with immunotherapy.
- 2 June 2022
- Published by Hindawi Limited in Journal of Immunology Research
- Vol. 2022, 1-13
Open AccessImmunotherapy and Antivascular Targeted Therapy in Patients’ Treatment with Concurrent Malignant Tumors after Organ Transplantation: Opportunity or Challenge
Objective. To analyze the therapeutic effects and organ rejection of anti-PD-1 immunotherapy or antivascular targeting therapy on patients with combined malignancies after organ transplantation. Methods. We collected retrospective studies on “post-transplantation, cancer, immunotherapy, and vascular targeting therapy” in Embase, Wanfang database, Cochrane Library, VIP databases, CNKI, and PubMed, and the case data were organized and analyzed. Results. Data from only 40 papers met our requirements, which included 2 literature reviews, 4 original researches, and 34 case reports from 2016 to 2020. A total of 40 studies involving 66 patients were included, who were divided into 3 groups (patients using CTLA-4 inhibitors, group 1; patients who received sequential or concurrent anti-PD-1 and anti-CTLA-4 therapy, group 2; and patients using PD-1/PD-L1 inhibitors, group 3). There was no statistical difference in patients’ DCR between the three groups ( ). Also, compared with group 2, there was no statistically significant difference in recipient organ rejection in group 1 and group 3 ( ). The DCR rate for antivascular targeted therapy is approximately 60%. Conclusions. Immunotherapy should be carefully selected for patients with combined malignancies after organ transplantation. Antivascular targeted therapy is one of the options worth considering; the risk of side effects of drug therapy is something that needs to be closely monitored when combined with immunotherapy.
- Open Access
- 20 May 2022
- Published by Hindawi Limited in Journal of Oncology
- Vol. 2022, 1-9
Diosmetin Affects Gene Expression on Human Lung Adenocarcinoma Cells
Objective. This study was aimed at investigating the effects of diosmetin (a natural flavonoid) on the gene expression of human lung adenocarcinoma (LUAD) cells. Methods. HCC827 and A549 cells were used. MTT and colony formation assay were used to investigate the effects of diosmetin on cell proliferation and colony forming activity. The expression of mRNA, microRNA, and lncRNA in HCC827 and A549 cell lines after diosmetin treatment was measured using DNA microarray, microRNA chromatin immunoprecipitation assay (ChIP), and long noncoding RNA (lncRNA) ChIP. Part of the results were cross-validated by quantitative reverse transcription PCR (RT-qPCR), while some others were analyzed using bioinformatic tools. Results. Diosmetin inhibited proliferation and colony formation of HCC827 and A549 cells. Investigation on gene expression profiles of A549 and HCC827 cells revealed that compared with the control group, diosmetin can up- or downregulated the expression of mRNAs, microRNAs, and lncRNAs. The top three candidates in each RNA category were cross-validated by RT-qPCR, from which single peaks were observed in the melt curves, showing a great specificity. After a comprehensive selection of the results from the mRNA ChIP, we performed GO and KEGG functional clustering analyses on the differentially expressed genes. Conclusion. Diosmetin treatment induced gene expression of A549 and HCC827 cells. Our results will provide guidance for development of new diagnostic and therapeutic targets.
- 20 May 2022
- Published by Hindawi Limited in Journal of Oncology
- Vol. 2022, 1-9
Open AccessDiosmetin Affects Gene Expression on Human Lung Adenocarcinoma Cells
Objective. This study was aimed at investigating the effects of diosmetin (a natural flavonoid) on the gene expression of human lung adenocarcinoma (LUAD) cells. Methods. HCC827 and A549 cells were used. MTT and colony formation assay were used to investigate the effects of diosmetin on cell proliferation and colony forming activity. The expression of mRNA, microRNA, and lncRNA in HCC827 and A549 cell lines after diosmetin treatment was measured using DNA microarray, microRNA chromatin immunoprecipitation assay (ChIP), and long noncoding RNA (lncRNA) ChIP. Part of the results were cross-validated by quantitative reverse transcription PCR (RT-qPCR), while some others were analyzed using bioinformatic tools. Results. Diosmetin inhibited proliferation and colony formation of HCC827 and A549 cells. Investigation on gene expression profiles of A549 and HCC827 cells revealed that compared with the control group, diosmetin can up- or downregulated the expression of mRNAs, microRNAs, and lncRNAs. The top three candidates in each RNA category were cross-validated by RT-qPCR, from which single peaks were observed in the melt curves, showing a great specificity. After a comprehensive selection of the results from the mRNA ChIP, we performed GO and KEGG functional clustering analyses on the differentially expressed genes. Conclusion. Diosmetin treatment induced gene expression of A549 and HCC827 cells. Our results will provide guidance for development of new diagnostic and therapeutic targets.
- Open Access
- 25 February 2022
- Published by Hindawi Limited in Journal of Oncology
- Vol. 2022, 1-13
The Meta-Analysis of Bevacizumab Combined with Platinum-Based Treatment of Malignant Pleural Effusions by Thoracic Perfusion
Objective. To evaluate the safety of bevacizumab combined with platinum-based thoracic perfusion for treating lung cancer-related malignant pleural effusion (MPE) through meta-analysis. Methods. The CNKI, PubMed, Cochrane Library, Embase, Chinese Science and Technology Journal Database (VIP), and Wanfang Databases were searched for randomized controlled trials (RCTs) of bevacizumab combined with platinum-based thoracic perfusion for the treatment of MPE. The references included in the articles were manually searched for additional studies. A meta-analysis of the RCTs was conducted using the RevMan 5.3 application. Results. A total of 8 studies involving 540 patients (271 cases in the test group and 269 cases in the control group) were included in the meta-analysis. The test group had a significantly greater risk of elevated blood pressure as well as a higher rate of complete remission (CR) compared to the control group ( ). In contrast, the incidence of partial remission (PR) was only slightly higher in the test group ( ), and the risks of leukopenia, vomiting or nausea, rhinorrhea, diarrhea, gastrointestinal bleeding or hemoptysis, proteinuria, abnormal kidney and liver function, arrhythmia, and rashes were not significantly different between the test and control groups ( ). Conclusion. Bevacizumab combined with platinum-based thoracic perfusion can achieve CR of MPE in patients with advanced lung cancer without significantly increasing the risk of adverse effects. The rate of PR was similar for the combination treatment and platinum-based infusion.
- 25 February 2022
- Published by Hindawi Limited in Journal of Oncology
- Vol. 2022, 1-13
Open AccessThe Meta-Analysis of Bevacizumab Combined with Platinum-Based Treatment of Malignant Pleural Effusions by Thoracic Perfusion
Objective. To evaluate the safety of bevacizumab combined with platinum-based thoracic perfusion for treating lung cancer-related malignant pleural effusion (MPE) through meta-analysis. Methods. The CNKI, PubMed, Cochrane Library, Embase, Chinese Science and Technology Journal Database (VIP), and Wanfang Databases were searched for randomized controlled trials (RCTs) of bevacizumab combined with platinum-based thoracic perfusion for the treatment of MPE. The references included in the articles were manually searched for additional studies. A meta-analysis of the RCTs was conducted using the RevMan 5.3 application. Results. A total of 8 studies involving 540 patients (271 cases in the test group and 269 cases in the control group) were included in the meta-analysis. The test group had a significantly greater risk of elevated blood pressure as well as a higher rate of complete remission (CR) compared to the control group ( ). In contrast, the incidence of partial remission (PR) was only slightly higher in the test group ( ), and the risks of leukopenia, vomiting or nausea, rhinorrhea, diarrhea, gastrointestinal bleeding or hemoptysis, proteinuria, abnormal kidney and liver function, arrhythmia, and rashes were not significantly different between the test and control groups ( ). Conclusion. Bevacizumab combined with platinum-based thoracic perfusion can achieve CR of MPE in patients with advanced lung cancer without significantly increasing the risk of adverse effects. The rate of PR was similar for the combination treatment and platinum-based infusion.